GHRP 2: Growth Hormone Releasing Peptide
98% (HPLC on request)
C42H50N8O5 Molecular Weight: 749.9 CAS No.: 87616-84-0
Growth Hormone Releasing Peptide-2 (GHRP 2) is a peptide made up of just six amino acids, which stimulates secretion of endogenous GH. Research shows GHRP 2 can stimulate the pituitary to increase secretion of GH by 7-15 times, stimulating ghrelin receptors to promote appetite. GHRP 2 acts as a synthetic ghrelin analogue that stimulates the release of an endogeneous growth hormone within the somatotropes of the anterior pituitary. Specifically, GHRP 2 will increase the number of somatotropes in a GH pulse by limiting the amount of somatostatin present while standard GHRH increases the amplitude at which the pituitary cells pulse.
The main effects of GHRP 2 are GH secretion, appetite enhancement, fat mass decrease and muscle mass increase, lowering of cholesterol level, skin and bone strengthening, protection of the liver and anti-inflammatory action. GHRP 2 possesses many repair properties that can be attributed to its immune boosting function. GHRP 2 has been shown to increase prolactin, aldosterone and cortisol levels and in some cases may not be the peptide of choice.
Content and Potency: 1 x 5mL at 2000mcg/ml ready-to-inject subcutaneous.
0.10ml daily 5 days out of 7 between 6 – 8pm (10 weeks supply).
Transdermal Option: 200mcg/mL x 50mL – Apply 1mL daily 5 days out of 7. (10 weeks supply).
Growth Hormone Releasing Peptide -2 (GHRP 2), like ghrelin, increases food intake in healthy men.
Blandine Laferrère, Cynthia Abraham, Colleen D. Russell, and Cyril Y. Bowers
The publisher’s final edited version of this article is available free at J Clin Endocrinol Metab
GHRP 2 is a synthetic agonist of ghrelin, the newly-discovered gut peptide which binds to the growth hormone (GH) secretagogue receptor. Ghrelin has been shown to have two major effects, stimulating both GH secretion and appetite/meal initiation. GHRP 2 has been extensively studied for its utility as a growth hormone secretagogue (GHS). Animal studies have shown its effect on food intake. We subcutaneously infused 7 lean, healthy males with GHRP 2 (1μg/kg/h) or saline for 270 minutes and then measured their intake of an ad libitum, buffet-style meal. Similar to what has been reported for ghrelin administration, our subjects ate 35.9±10.9 % more when infused with GHRP 2 vs. saline, with every subject increasing their intake even when calculated per kg body weight (136.0±13.0 kJ/kg vs 101.3±10.5 kJ/kg, p=0.008). The macronutrient composition of consumed food was not different between conditions. As expected, serum GH levels rose significantly during GHRP 2 infusion (AUC 5550±1090 μg/L/240 min vs. 412±161 μg/L/240 min, p=0.003). This data is the first to demonstrate that GHRP 2, like ghrelin, increases food intake, suggesting that GHRP 2 is a valuable tool for investigating ghrelin effects on eating behaviour in humans.